Drugmakers are racing to develop a new generation of Covid-19 medicines to make them easier to give to patients and to stay ahead of virus mutations that could make some current drugs less effective.
The drugs, known as monoclonal antibodies, are lab-engineered versions of antibodies that simulate the body’s natural immune response to viruses. They are considered among the most promising for preventing infected patients from developing severe or fatal symptoms and keeping them out of the hospital. After catching Covid-19, President
was treated with one of the drugs and credited it with his speedy recovery. Doctors say the drugs will continue to be important treatments for the foreseeable future as vaccines become more widely available.
When the first generation of drugs were authorized by the U.S. Food and Drug Administration in November to treat patients not yet sick enough to be hospitalized, public health officials worried that there